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Resveratrol inhibits PAH bioactivation through reduced expression of the CYP1A1 and CYP1B1 genes in human bronchial epithelial
cells. Ad libitum access to a diet containing resveratrol showed no effect on benzo[a]pyrene-induced lung tumorigenesis in A/J mice.
Also, resveratrol did not change CYP1A1 and CYP1B1 gene expression or benzo[a]pyrene protein adduct levels in the lung tissue.
The lack of chemopreventive activity may have been caused by insufficient concentrations or nonreactive forms of resveratrol in the
lungs.
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Lung cancer is the major cause of cancer-related mortality
worldwide and tobacco smoke is established as the primary
aetiologic factor for the disease. Other risk factors are occupational
exposure and urban air pollution (Twombly, 2003). Today, 25–
30% of adults in western populations are active smokers, while the
number is increasing in developing countries (Peto et al, 1996).
The cancer has proven difficult to control with conventional
therapeutic and surgical approaches, and the prognosis is poor
with an overall 5-year survival rate of 10–14% in the USA (Jemal
et al, 2004). The use of naturally occurring or synthetic agents to
prevent, inhibit or reverse lung carcinogenesis would there-
fore greatly benefit public health. Resveratrol (trans-3,40,5-
trihydroxystilbene) is a phenolic phytoalexin present in wines,
berries and nuts, which has shown chemopreventive potential
(Jang et al, 1997).
Benzo[a]pyrene (B[a]P) is a major carcinogenic constituent in
tobacco smoke (Hecht, 2003). It is metabolically activated by the
cytochrome P450 (CYP) system to reactive diolepoxides which are
capable of interacting with DNA or proteins to form adducts. In
the lung, CYP1A1 and CYP1B1 are important in the biotransfor-
mation of B[a]P, and their expression is inhibited by resveratrol in
vitro (Ciolino and Yeh, 1999; Mollerup et al, 2001; Berge et al,
2004b). Accordingly, in human bronchial epithelial cells, inhibition
of CYP1A1 and CYP1B1 was accompanied by reduced formation of
the ultimate carcinogen BPDE-I and BPDE–DNA adducts
(Mollerup et al, 2001; Berge et al, 2004b).
The anticancer effect of resveratrol has previously been studied
with conflicting results in vivo. In this study, we addressed the
effect of resveratrol on initiation of lung tumorigenesis in A/J mice.
Mice with free access to a diet containing resveratrol were
repeatedly exposed to B[a]P by gavage. The effect of resveratrol
on the expression level of CYP1A1 and CYP1B1 in the lung tissue
was determined by quantitative real-time RT–PCR, and hydro-
lysed B[a]P–protein adducts were measured by HPLC. Further-
more, the development of lung tumours in response to resveratrol
was investigated.
MATERIALS AND METHODS
Animal handling and treatment
A total of 150 female A/JOlaHsd mice (Harlan, UK) were housed in
an animal facility with a 12-h light/dark cycle at 211C and 55% RH.
The mice had ad libitum access to tap water and diet throughout
the study. Diet was prepared daily by dispensing EtOH only
(solvent control) or resveratrol/EtOH to a pulverised standard diet
(RM1)(SDS, UK) (0.4%ww
 1), and the solvent was evaporated
overnight in the dark. Food dishes were replaced each morning
and were shaded by metal plates over the cages. The stability of
trans-resveratrol in the diet was tested by HPLC, and no
decomposition was found. The mice consumed 5–6gday
 1,
resulting in 6–8mgkg
 1 resveratrol ingested. The administered
dose of resveratrol was chosen based on analyses described in the
literature (Kimura and Okuda, 2001; Asensi et al, 2002). After 1
week on the diet, the B[a]P exposure regimes were started on 6-
week-old animals. B[a]P (in corn oil) was delivered by a gastric
tube (i.g.) once a week for 8 weeks, giving a total dose of 80 or
300mgkg
 1. Control animals received corn oil only. There were no
differences in the food intake, weight increase, or behaviour
between the groups, and no indications of toxicity of resveratrol or
B[a]P (data not shown). The animals were randomly divided into
six groups (n¼25). At 24h after the last dose of B[a]P, five
animals in each group were killed by cervical dislocation. The
lungs and livers were excised, snapfrozen in liquid nitrogen, and
stored at  701C. At 5 months after the last dose of B[a]P, the rest
of the animals were killed. The lungs were fixed in Bouin’s fluid.
The tracheae were removed and the individual lobes were dissected
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sfree and transferred to 96% ethanol. The number of tumours was
determined by manual counting and the size scored according to a
ruler in the microscope. Lung tumour development was as
expected for the strain, doses and exposure regimen of B[a]P
(Hecht et al, 1994). In vivo testing was performed according to
Workman et al (1998), and all animal-handling and experimental
procedures were conducted in conformity with the laws and
regulations controlling experiments on live animals in Norway and
the European Convention for the Protection of Vertebrate Animals
used in Experimental and Other Scientific Purposes.
Real-time RT–PCR
Total RNA was extracted from tissue and mRNA was reverse
transcribed using random primers as described previously (Berge
et al, 2004b). Sequences for the PCR primers were: CYP1A1
forward, 50-ACC TTC CGG CAT TCA TCC TT-30; CYP1A1 reverse,
50-GCC ATT CAG ACT TGT ATC TCT TGT G-30; CYP1B1 forward,
50-GTG GCT GCT CAT CCT CTT TAC C-30; CYP1B1 reverse,
50-CCC ACA ACC TGG TCC AAC TC-30; b-actin forward, 50-GAC
AGC ACA GCC TGG ATG GCT A-30; b-actin reverse, 50-GTG AAA
AGA TGA CCC AGA TCA-30. Real-time PCR was performed on an
ABI PRISM 5700 (Applied Biosystems, Foster City, CA, USA) with
SYBRgreen I (40 cycles of 951C15s
 1,6 0 1C1min
 1). The amount
of target cDNA in each sample was established by determining a
fractional PCR threshold cycle number (Ct). The relative expres-
sion of each gene normalised to b-actin was calculated as 2
 DCt,
where DCt¼Ctgene Ctb-actin.
B[a]P–protein adduct measurements
B[a]P–protein adducts were measured as released B[a]P-tetrol
after acid hydrolysis. The preparation of the tissue and purification
by Sep-Pak C18 cartridge (Millipore Corporation, Milford, MA,
USA) was performed as described in Berge et al (2004a). High-
performance liquid chromatography (HPLC) separation of the
B[a]P-tetrols was performed on a Hypercil C18 column
4.6 150mm and 5mm (Agilent Technologies, Waldbronn,
Germany) in a linear gradient of 30–100% methanol for 40min
on an Agilent 1100 system. The following fluorescence conditions
were used: 0min, ex 341/em 381; 20min, ex 253/em 410; 27min, ex
380/em 431. The concentrations of B[a]P metabolites were
determined by comparison to standards from the NIH Chemical
Carcinogen Repository (Midwest Research Institute, Kansas City,
MO, USA).
Tissue distribution of resveratrol
Lung tissue, intestinal tissue (small intestines and colonic mucosa
combined) and faeces were collected. The tissue samples were
homogenised by a polytron in NaAc (0.1 M, pH 5.0), and further
incubated with b-glucoronidase and arylsulphatase (Roche) at
371C overnight to cleave the sulphate and glucuronide conjugates
of resveratrol. The samples were sonicated three times in EtOH,
centrifuged and the precipitates were washed with EtOH,
evaporated to dryness, dissolved in 3ml H2O and purified on
Sep-Pak cartridges (based on Vitrac et al, 2003). Resveratrol was
quantified by HPLC in a linear gradient of 10–100% methanol
using a diode array detector (DAD) at 306nm. The detection limit
of resveratrol by HPLC was approximately 1pmol (signal to
noise¼3).
Statistical analyses
For the analysis of gene expression, protein adducts and tumour
size, means were compared by the independent-samples t-test.
With significant variations in standard deviation, Welch correc-
tion was applied. Variations in the number of tumours were
investigated by Fisher’s exact test and w
2 test (SPSS, Chicago,
IL, USA).
RESULTS
CYP1A1 and CYP1B1 gene expression was measured in the lungs
of mice given a weekly dose of B[a]P for 8 consecutive weeks. The
expression level of CYP1A1 was found to be low in the control and
low-dose B[a]P groups, whereas a dose of 300mgkg
 1 B[a]P
significantly induced the gene (Figure 1A). The addition of
resveratrol in the diet did not significantly affect the expression
levels of CYP1A1 in any group (solvent only, 80mgkg
 1 B[a]P, or
300mgkg
 1 B[a]P) compared to the respective controls. B[a]P was
not found to induce significant changes in the mRNA level of
CYP1B1, while the basal expression level of the gene was higher
than for CYP1A1. Resveratrol did not alter the expression level of
CYP1B1 significantly, regardless of B[a]P exposure dose (data not
shown).
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Figure 1 The mice were orally injected with corn oil or B[a]P (mgkg
 1
cumulative dose), and received resveratrol (RSV) in the diet as indicated.
They were killed 24h after the eight dose of B[a]P. (A) Real-time RT–PCR
measurement of CYP1A1 expression relative to the expression of b-actin
in lung tissue. Expression levels were normalised to b-actin. Columns and
error bars represent the mean and s.d. (n¼5). *Lane 1 vs lane 5, P¼0.01,
independent samples t-test with Welch correction. (B) Effect of resveratrol
on B[a]P–protein adduct formation in lung tissue. The levels of the protein-
adduct hydrolysis product B[a]P-tetrol I-1 were measured by fluorescence
HPLC. Columns and error bars represent the mean and s.d. (n¼5). **Lane
1 vs lane 3, P¼0.0001 independent samples t-test. ***Lane 1 vs lane 5,
P¼0.004 independent samples t-test with Welch correction.
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sThe hydrolysis of protein adducts resulted in various amounts
of B[a]P-tetrols, of which B[a]P-tetrol I-1 (a derivate of the B[a]P-
oxide BPDE-I) was the most abundant. The levels of B[a]P-tetrol I-
1 increased dose-dependently in response to B[a]P (Figure 1B). No
significant effect of resveratrol was found on the level of B[a]P-
tetrol I-1 protein adducts at either low or high dose of B[a]P,
compared to the corresponding controls. The results for the other
B[a]P hydrolysis products showed similar trends or were below
detection limits (data not shown). B[a]P–protein adducts were
also measured in liver tissue from the mice. As for the lung, no
effect of resveratrol was found (data not shown).
The remaining animals were killed 5 months after the last dose
of B[a]P and lung tumours were examined. The number of
tumours increased dose-dependently with B[a]P exposure, while
no significant effect of resveratrol was found (Table 1). Similarly,
resveratrol was not found to significantly alter the size of the
tumours when the respective groups were compared.
By HPLC, no resveratrol or resveratrol conjugates were found in
the lung tissue of animals after dietary administration of the
compound. However, resveratrol could be detected in intestinal
tissue (89.9pmolg
 1 tissue) and faeces (9.6nmolg
 1 faeces).
DISCUSSION
We have previously shown that resveratrol inhibits CYP1A1 and
CYP1B1 expression, as well as the formation of B[a]P–protein and
–DNA adducts in cultured human bronchial epithelial cells
(Mollerup et al, 2001; Berge et al, 2004b). To explore the lung
cancer chemopreventive potential of resveratrol in a physiologi-
cally relevant in vivo scenario, the compound was administered
orally to A/J mice. This strain is frequently used as an experimental
model of lung carcinogenesis, and is well suited as the mice readily
produce lung tumours after oral B[a]P exposure (Hecht et al,
1994). In short, the results of our study under these conditions are
not indicative of an effect of resveratrol on either the number or
size of B[a]P-induced lung tumours in A/J mice.
The effect of resveratrol on the development of different cancer
types has previously been assayed in several in vivo studies with
various results. Our data resemble the findings of Hecht et al (1999),
who did not observe any effect on lung tumour multiplicity when
resveratrol was given in the diet to A/J mice from 1 week after oral
carcinogen exposure. To study the effect during initiation, however,
resveratrol was administered from 1 week before the start of B[a]P
exposure and continued throughout the study period. Resveratrol
was not found to significantly alter the expression levels of CYP1A1
or CYP1B1 or the B[a]P protein–adduct level in lung, contrasting
our in vitro data (Mollerup et al, 2001; Berge et al, 2004b). Few
studies have quantitatively addressed the effect of resveratrol in
intact lung tissue. In one study, subcutaneous injection of
resveratrol was by semiquantitative immunohistochemistry or
Western blotting found to inhibit the level of B[a]P-induced
CYP1A1 in mouse lung tissue (Revel et al,2 0 0 3 ) .
The efficacy of orally administered resveratrol will, in addition
to the mechanism of action, depend on its absorption, metabolism,
and pharmacokinetic tissue distribution. To resemble a relevant
physiological condition, we chose to deliver resveratrol in the diet,
as oral administration would be a preferable route in cancer
chemoprevention. Also, repeated intake could result in an elevated
basal level of the compound in the plasma (Scalbert and Williamson,
2000; Asensi et al, 2002). By autoradiography and HPLC, intact
trans-resveratrol has been detected in mouse lung tissue after a
single intragastric delivery of various doses (Vitrac et al, 2003; Sale
et al, 2004). On the other hand, recent studies have suggested rapid
clearance in mice tissue after a single oral dose of resveratrol (Asensi
et al,2 0 0 2 ;Y uet al, 2002). While both resveratrol and its conjugates
have been detected in the small intestine and colonic mucosa, the
full pharmacologic distribution is not known (Vitrac et al, 2003; Sale
et al, 2004). Due to the lack of in vivo effect in the present study, we
investigated the bioavailability of resveratrol in the mouse tissue. No
resveratrol or resveratrol conjugates were found by HPLC in the
lung tissue of animals receiving the compound in the diet.
Resveratrol is known to undergo metabolic phase II reactions
involving conjugation with sulphate and glucuronic acid, which
may influence the biological effect of the compound. The extent of
such modification in various tissues is not known (Scalbert and
Williamson, 2000; Yu et al, 2002). Resveratrol has shown anti-
carcinogenic effects in colon, but the data are conflicting. In Min
mice, a strain predisposed to develop intestinal tumours,
resveratrol administered in the drinking water strongly reduced
the formation of colon and small intestinal tumours (Schneider
et al, 2001). However, the doses used in this study have been
questioned by Ziegler et al (2004), who found no effect of
resveratrol in the diet on either COX-2 expression or the number
of tumours. In the negative studies, including the present,
resveratrol given in the diet may not have reached the target
tissue in sufficient concentrations or biological active form.
However, the potential beneficial effects on health justify further
studies of the absorption, metabolism and disposition of trans-
resveratrol in the tissue in question.
Inhibition of CYP-gene expression accompanied by a reduced
formation of carcinogenic B[a]P metabolites and DNA adducts
may be an important step in preventing or lowering the risk of
lung cancer. Data concerning effects of resveratrol on the
prevention of cancer are ambiguous and lack a link between
target organ, efficacy in vivo and the activity observed in vitro
(Gescher and Steward, 2003). The current data, based on oral
administration, do not lend support for resveratrol as a
physiologically effective chemopreventive agent for the inhibition
of PAH-induced lung cancer.
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